Showing results (1-10 of 301) with videos related to
Sort By:
Pageof 31
European Journal of Cancer (Oxford, England : 1990)|October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Mark J Ratain, Garth W StrohbehnClinical and Translational Science|August 26, 2025
Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling AuthorityMark J Ratain, Garth W StrohbehnClinical Pharmacology and Therapeutics|June 4, 2020
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19Garth W Strohbehn, Pankti D Reid, Mark J RatainClinical Trials (London, England)|December 27, 2023
Optimizing the doses of cancer drugs after usual dose findingGarth W Strohbehn, Walter M Stadler, Philip S Boonstra, et al.Clinical Pharmacology and Therapeutics|April 17, 2020
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking ValueAnthony V Serritella, Garth W Strohbehn, Daniel A Goldstein, et al.Value in Health Regional Issues|April 8, 2022
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance PlanGarth W Strohbehn, Jennifer H Cooperrider, Dali Yang, et al.JCO Oncology Practice|July 14, 2023
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas EmissionsSofia I Jacobson, Alec J Kacew, Randall W Knoebel, et al.Cancer Journal (Sudbury, Mass.)|August 1, 2020
Interventional PharmacoeconomicsDaniel A Goldstein, Garth W Strohbehn, Anthony V Serritella, et al.NPJ Breast Cancer|March 15, 2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savingsPo-Hung Hsieh, Alec J Kacew, Marie Dreyer, et al.The Lancet. Oncology|October 3, 2024
The tyranny of non-inferiority trialsIan F Tannock, Marc Buyse, Mickael De Backer, et al.Pageof 31